Department of Anesthesiology, General Hospital of Tianjin Medical University, Tianjin 300052, China.
Department of Critical Care Medicine, General Hospital of Tianjin Medical University, Tianjin 300052, China.
J Immunol Res. 2016;2016:9276986. doi: 10.1155/2016/9276986. Epub 2016 Dec 8.
Chronic liver allograft dysfunction (CLAD) remains the most common cause of patient morbidity and allograft loss in liver transplant patients. However, the pathogenesis of CLAD has not been completely elucidated. By establishing rat CLAD models, in this study, we identified the informative CLAD-associated genes using isobaric tags for relative and absolute quantification (iTRAQ) proteomics analysis and validated these results in recipient rat liver allografts. CXCL4, CXCR3, EGFR, JAK2, STAT3, and Collagen IV were associated with CLAD pathogenesis. We validated that CXCL4 is upstream of these informative genes in the isolated hepatic stellate cells (HSC). Blocking CXCL4 protects against CLAD by reducing liver fibrosis. Therefore, our results indicated that therapeutic approaches that neutralize CXCL4, a newly identified target of fibrosis, may represent a novel strategy for preventing and treating CLAD after liver transplantation.
慢性肝移植功能障碍 (CLAD) 仍然是肝移植患者患者发病率和移植物丧失的最常见原因。然而,CLAD 的发病机制尚未完全阐明。通过建立大鼠 CLAD 模型,本研究使用同位素标记相对和绝对定量 (iTRAQ) 蛋白质组学分析鉴定了有信息意义的 CLAD 相关基因,并在受体大鼠肝移植物中验证了这些结果。CXCL4、CXCR3、EGFR、JAK2、STAT3 和 Collagen IV 与 CLAD 的发病机制有关。我们验证了在分离的肝星状细胞 (HSC) 中,CXCL4 是这些有信息基因的上游。阻断 CXCL4 通过减少肝纤维化来预防 CLAD。因此,我们的结果表明,中和 CXCL4 的治疗方法可能是预防和治疗肝移植后 CLAD 的一种新策略,而 CXCL4 是纤维化的一个新靶点。